메뉴 건너뛰기




Volumn 755, Issue , 2015, Pages 50-57

A step ahead of PPARγ full agonists to PPARγ partial agonists: Therapeutic perspectives in the management of diabetic insulin resistance

Author keywords

Adverse effects; Cardiovascular events; Diabetes mellitus; PPAR full agonists; PPAR partial agonists

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4,6 TRISUBSTITUTED 5 PYRIMIDINECARBOXYLIC ACID; 4 [2 (4 ISOPROPYLBENZAMIDO)ETHOXY]BENZOIC ACID; AMORFRUTIN; ANTIDIABETIC AGENT; ARHALOFENATE; BALAGLITAZONE; CMHX 008; FALCARINDIOL; GLUCOSE; GQ 16; HALOFENATE; HONOKIOL; INT 131; KDT 501; METFORMIN; MK 0533; PA 082; PAM 1616; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; T 2384; UNCLASSIFIED DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

EID: 84925089002     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.02.043     Document Type: Review
Times cited : (56)

References (62)
  • 1
    • 64949195390 scopus 로고    scopus 로고
    • Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development
    • B.D. Abbott Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development Reprod. Toxicol. 27 2009 246 257
    • (2009) Reprod. Toxicol. , vol.27 , pp. 246-257
    • Abbott, B.D.1
  • 2
    • 67649980379 scopus 로고    scopus 로고
    • Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume
    • rd, T.E. Akiyama, C.H. Chang, L. Colwell, S. Debenham, T. Doebber, M. Einstein, K. Liu, M.E. McCann, D.E. Moller, E.S. Muise, Y. Tan, J.R. Thompson, K.K. Wong, M. Wu, L. Xu, P.T. Meinke, J.P. Berger, and H.B. Wood Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume J. Med. Chem. 52 2009 3846 3854
    • (2009) J. Med. Chem. , vol.52 , pp. 3846-3854
    • Acton, J.J.1    Akiyama, T.E.2    Chang, C.H.3    Colwell, L.4    Debenham, S.5    Doebber, T.6    Einstein, M.7    Liu, K.8    Mccann, M.E.9    Moller, D.E.10    Muise, E.S.11    Tan, Y.12    Thompson, J.R.13    Wong, K.K.14    Wu, M.15    Xu, L.16    Meinke, P.T.17    Berger, J.P.18    Wood, H.B.19
  • 7
    • 84862684037 scopus 로고    scopus 로고
    • The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
    • L. Azoulay, H. Yin, K.B. Filion, J. Assayag, A. Majdan, M.N. Pollak, and S. Suissa The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study BMJ 344 2012 e3645
    • (2012) BMJ , vol.344
    • Azoulay, L.1    Yin, H.2    Filion, K.B.3    Assayag, J.4    Majdan, A.5    Pollak, M.N.6    Suissa, S.7
  • 8
    • 67349188030 scopus 로고    scopus 로고
    • Emerging role of PPAR ligands in the management of diabetic nephropathy
    • P. Balakumar, M.K. Arora, and M. Singh Emerging role of PPAR ligands in the management of diabetic nephropathy Pharmacol. Res. 60 2009 170 173
    • (2009) Pharmacol. Res. , vol.60 , pp. 170-173
    • Balakumar, P.1    Arora, M.K.2    Singh, M.3
  • 9
    • 84861740440 scopus 로고    scopus 로고
    • PPAR ligands and cardiovascular disorders: friend or foe
    • P. Balakumar, and G. Jagadeesh PPAR ligands and cardiovascular disorders: friend or foe Curr. Mol. Pharmacol. 5 2012 219 223
    • (2012) Curr. Mol. Pharmacol. , vol.5 , pp. 219-223
    • Balakumar, P.1    Jagadeesh, G.2
  • 10
    • 84863696819 scopus 로고    scopus 로고
    • Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders
    • P. Balakumar, and S. Kathuria Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders Br. J. Pharmacol. 166 2012 1981 1992
    • (2012) Br. J. Pharmacol. , vol.166 , pp. 1981-1992
    • Balakumar, P.1    Kathuria, S.2
  • 11
    • 83755220049 scopus 로고    scopus 로고
    • Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
    • P. Balakumar, and N. Mahadevan Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br. J. Pharmacol. 165 2012 373 379
    • (2012) Br. J. Pharmacol. , vol.165 , pp. 373-379
    • Balakumar, P.1    Mahadevan, N.2
  • 14
    • 33947134267 scopus 로고    scopus 로고
    • Thiazolidinediones and the risk of edema: a meta-analysis
    • H.D. Berlie, J.S. Kalus, and L.A. Jaber Thiazolidinediones and the risk of edema: a meta-analysis Diabetes Res. Clin. Pract. 76 2007 279 289
    • (2007) Diabetes Res. Clin. Pract. , vol.76 , pp. 279-289
    • Berlie, H.D.1    Kalus, J.S.2    Jaber, L.A.3
  • 16
    • 33846623798 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
    • J.D. Brown, and J. Plutzky Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets Circulation 115 2007 518 533
    • (2007) Circulation , vol.115 , pp. 518-533
    • Brown, J.D.1    Plutzky, J.2
  • 17
  • 18
    • 65649104489 scopus 로고    scopus 로고
    • MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation
    • A. Chandalia, H.J. Clarke, L.E. Clemens, B. Pandey, V. Vicena, P. Lee, B.E. Lavan, and F.M. Gregoire MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation PPAR Res. 2009 2009 706852
    • (2009) PPAR Res. , vol.2009 , pp. 706852
    • Chandalia, A.1    Clarke, H.J.2    Clemens, L.E.3    Pandey, B.4    Vicena, V.5    Lee, P.6    Lavan, B.E.7    Gregoire, F.M.8
  • 19
    • 84860838260 scopus 로고    scopus 로고
    • NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile
    • S. Chaudhary, A. Dube, V. Kothari, N. Sachan, and C.D. Upasani NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile Eur. J. Pharmacol. 684 2012 154 160
    • (2012) Eur. J. Pharmacol. , vol.684 , pp. 154-160
    • Chaudhary, S.1    Dube, A.2    Kothari, V.3    Sachan, N.4    Upasani, C.D.5
  • 20
    • 33745495558 scopus 로고    scopus 로고
    • Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    • V.T. Chetty, and A.M. Sharma Can PPARgamma agonists have a role in the management of obesity-related hypertension? Vasc. Pharmacol. 45 2006 46 53
    • (2006) Vasc. Pharmacol. , vol.45 , pp. 46-53
    • Chetty, V.T.1    Sharma, A.M.2
  • 22
    • 84863718935 scopus 로고    scopus 로고
    • Bladder cancer: pioglitazone increases risk of bladder cancer
    • M. Clyne Bladder cancer: pioglitazone increases risk of bladder cancer Nat. Rev. Urol. 9 2012 353
    • (2012) Nat. Rev. Urol. , vol.9 , pp. 353
    • Clyne, M.1
  • 25
    • 82555175836 scopus 로고    scopus 로고
    • Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data
    • A.M. Gallagher, L. Smeeth, S. Seabroke, H.G. Leufkens, and T.P. van Staa Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data PLoS One 6 2011 e28157
    • (2011) PLoS One , vol.6
    • Gallagher, A.M.1    Smeeth, L.2    Seabroke, S.3    Leufkens, H.G.4    Van Staa, T.P.5
  • 26
    • 67649598394 scopus 로고    scopus 로고
    • MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema
    • F.M. Gregoire, F. Zhang, H.J. Clarke, T.A. Gustafson, D.D. Sears, S. Favelyukis, J. Lenhard, D. Rentzeperis, L.E. Clemens, Y. Mu, and B.E. Lavan MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema Mol. Endocrinol. 23 2009 975 988
    • (2009) Mol. Endocrinol. , vol.23 , pp. 975-988
    • Gregoire, F.M.1    Zhang, F.2    Clarke, H.J.3    Gustafson, T.A.4    Sears, D.D.5    Favelyukis, S.6    Lenhard, J.7    Rentzeperis, D.8    Clemens, L.E.9    Mu, Y.10    Lavan, B.E.11
  • 27
    • 84898891705 scopus 로고    scopus 로고
    • Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis
    • S. He, Y.H. Tang, G. Zhao, X. Yang, D. Wang, and Y. Zhang Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis Tumour Biol. 35 2014 2095 2102
    • (2014) Tumour Biol. , vol.35 , pp. 2095-2102
    • He, S.1    Tang, Y.H.2    Zhao, G.3    Yang, X.4    Wang, D.5    Zhang, Y.6
  • 30
    • 79953236112 scopus 로고    scopus 로고
    • Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials
    • A.V. Hernandez, A. Usmani, A. Rajamanickam, and A. Moheet Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials Am. J. Cardiovasc. Drugs 11 2011 115 128
    • (2011) Am. J. Cardiovasc. Drugs , vol.11 , pp. 115-128
    • Hernandez, A.V.1    Usmani, A.2    Rajamanickam, A.3    Moheet, A.4
  • 31
    • 67149146438 scopus 로고    scopus 로고
    • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    • P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, M. Hanefeld, N.P. Jones, M. Komajda, J.J. McMurray, and RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
    • (2009) Lancet , vol.373 , pp. 2125-2135
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3    Curtis, P.S.4    Gomis, R.5    Hanefeld, M.6    Jones, N.P.7    Komajda, M.8    Mcmurray, J.J.9    Record Study Team10
  • 32
    • 84925160303 scopus 로고    scopus 로고
    • accessed 04.10.14
    • http://www.diabetes.org.my/article.php?aid=837 (accessed 04.10.14.).
  • 33
    • 69749102008 scopus 로고    scopus 로고
    • Distal upper and lower limb fractures associated with thiazolidinedione use
    • S.G. Jones, S.R. Momin, M.W. Good, T.K. Shea, and K. Patric Distal upper and lower limb fractures associated with thiazolidinedione use Am. J. Manag. Care 15 2009 491 496
    • (2009) Am. J. Manag. Care , vol.15 , pp. 491-496
    • Jones, S.G.1    Momin, S.R.2    Good, M.W.3    Shea, T.K.4    Patric, K.5
  • 34
    • 69949096990 scopus 로고    scopus 로고
    • Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
    • D.N. Juurlink, T. Gomes, L.L. Lipscombe, P.C. Austin, J.E. Hux, and M.M. Mamdani Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study BMJ 339 2009 b2942
    • (2009) BMJ , vol.339 , pp. 2942
    • Juurlink, D.N.1    Gomes, T.2    Lipscombe, L.L.3    Austin, P.C.4    Hux, J.E.5    Mamdani, M.M.6
  • 36
    • 63849177352 scopus 로고    scopus 로고
    • INT-131, a PPARgamma agonist for the treatment of type 2 diabetes
    • U. Kintscher, and M. Goebel INT-131, a PPARgamma agonist for the treatment of type 2 diabetes Curr. Opin. Investig. Drugs 10 2009 381 387
    • (2009) Curr. Opin. Investig. Drugs , vol.10 , pp. 381-387
    • Kintscher, U.1    Goebel, M.2
  • 37
    • 84900399238 scopus 로고    scopus 로고
    • KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes
    • V.R. Konda, A. Desai, G. Darland, N. Grayson, and J.S. Bland KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes PLoS One 9 2014 e87848
    • (2014) PLoS One , vol.9
    • Konda, V.R.1    Desai, A.2    Darland, G.3    Grayson, N.4    Bland, J.S.5
  • 40
    • 53049098128 scopus 로고    scopus 로고
    • Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone
    • P.J. Larsen, K. Lykkegaard, L.K. Larsen, J. Fleckner, P. Sauerberg, K. Wassermann, and E.M. Wulff Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone Eur. J. Pharmacol. 596 2008 173 179
    • (2008) Eur. J. Pharmacol. , vol.596 , pp. 173-179
    • Larsen, P.J.1    Lykkegaard, K.2    Larsen, L.K.3    Fleckner, J.4    Sauerberg, P.5    Wassermann, K.6    Wulff, E.M.7
  • 41
    • 84863154767 scopus 로고    scopus 로고
    • Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice
    • D.H. Lee, H. Huang, K. Choi, C. Mantzoros, and Y.B. Kim Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice Am. J. Physiol. Endocrinol. Metab. 302 2012 E552 560
    • (2012) Am. J. Physiol. Endocrinol. Metab. , vol.302 , pp. E552-E560
    • Lee, D.H.1    Huang, H.2    Choi, K.3    Mantzoros, C.4    Kim, Y.B.5
  • 44
    • 77957223368 scopus 로고    scopus 로고
    • Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein
    • X. Liao, Y. Wang, and C.W. Wong Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein Br. J. Pharmacol. 161 2010 771 781
    • (2010) Br. J. Pharmacol. , vol.161 , pp. 771-781
    • Liao, X.1    Wang, Y.2    Wong, C.W.3
  • 45
    • 79953203593 scopus 로고    scopus 로고
    • Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
    • Y.K. Loke, C.S. Kwok, and S. Singh Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies BMJ 342 2011 d1309
    • (2011) BMJ , vol.342 , pp. 1309
    • Loke, Y.K.1    Kwok, C.S.2    Singh, S.3
  • 48
    • 84903893789 scopus 로고    scopus 로고
    • CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo
    • Y. Ming, X. Hu, Y. Song, Z.1. Liu, J. Li, R. Gao, Y. Zhang, H. Mei, T. Guo, L. Xiao, B. Wang, C. Wu, and X. Xiao CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo PLoS One 9 2014 e102102
    • (2014) PLoS One , vol.9
    • Ming, Y.1    Hu, X.2    Song, Y.3    Liu, Z.1.4    Li, J.5    Gao, R.6    Zhang, Y.7    Mei, H.8    Guo, T.9    Xiao, L.10    Wang, B.11    Wu, C.12    Xiao, X.13
  • 50
    • 84866358522 scopus 로고    scopus 로고
    • Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
    • A. Neumann, A. Weill, P. Ricordeau, J.P. Fagot, F. Alla, and H. Allemand Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study Diabetologia 55 2012 1953 1962
    • (2012) Diabetologia , vol.55 , pp. 1953-1962
    • Neumann, A.1    Weill, A.2    Ricordeau, P.3    Fagot, J.P.4    Alla, F.5    Allemand, H.6
  • 51
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471
    • (2007) N. Engl. J. Med. , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 52
    • 77954136691 scopus 로고    scopus 로고
    • Bone loss and fracture risk associated with thiazolidinedione therapy
    • D.M. Riche, and S.T. King Bone loss and fracture risk associated with thiazolidinedione therapy Pharmacotherapy 30 2010 716 727
    • (2010) Pharmacotherapy , vol.30 , pp. 716-727
    • Riche, D.M.1    King, S.T.2
  • 53
    • 84896711938 scopus 로고    scopus 로고
    • Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use
    • V. Romero, C. Peyton, I. Gray, A. Hemal, and R. Terlecki Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use BMC Urol. 14 2014 10
    • (2014) BMC Urol. , vol.14 , pp. 10
    • Romero, V.1    Peyton, C.2    Gray, I.3    Hemal, A.4    Terlecki, R.5
  • 54
    • 33646099930 scopus 로고    scopus 로고
    • MBX-102: A novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with type 2 diabetes mellitus (T2DM) on concomitant insulin therapy [abstract 44-OR]
    • J. Rosenstock, F. Flores-Losano, S. Schwartz, G. Gonzalez-Galvez, and D.B. Karpf MBX-102: A novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with type 2 diabetes mellitus (T2DM) on concomitant insulin therapy [abstract 44-OR] Diabetes 54 2005 A11
    • (2005) Diabetes , vol.54 , pp. A11
    • Rosenstock, J.1    Flores-Losano, F.2    Schwartz, S.3    Gonzalez-Galvez, G.4    Karpf, D.B.5
  • 55
    • 77958529709 scopus 로고    scopus 로고
    • Cardiovascular risk and thiazolidinediones - What do meta-analyses really tell us?
    • G. Schernthaner, and R.J. Chilton Cardiovascular risk and thiazolidinediones - what do meta-analyses really tell us? Diabetes Obes. Metab. 12 2010 1023 1035
    • (2010) Diabetes Obes. Metab. , vol.12 , pp. 1023-1035
    • Schernthaner, G.1    Chilton, R.J.2
  • 56
    • 77954328462 scopus 로고    scopus 로고
    • Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone
    • S. Seto, K. Okada, K. Kiyota, S. Isogai, M. Iwago, T. Shinozaki, Y. Kitamura, Y. Kohno, and K. Murakami Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone J. Med. Chem. 53 2010 5012 5024
    • (2010) J. Med. Chem. , vol.53 , pp. 5012-5024
    • Seto, S.1    Okada, K.2    Kiyota, K.3    Isogai, S.4    Iwago, M.5    Shinozaki, T.6    Kitamura, Y.7    Kohno, Y.8    Murakami, K.9
  • 57
    • 34548580881 scopus 로고    scopus 로고
    • Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis
    • S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 2007 1189 1195
    • (2007) JAMA , vol.298 , pp. 1189-1195
    • Singh, S.1    Loke, Y.K.2    Furberg, C.D.3
  • 58
    • 51349164431 scopus 로고    scopus 로고
    • Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events
    • C.I. Starner, J.A. Schafer, A.H. Heaton, and P.P. Gleason Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events J. Manag. Care Pharm. 14 2008 523 531
    • (2008) J. Manag. Care Pharm. , vol.14 , pp. 523-531
    • Starner, C.I.1    Schafer, J.A.2    Heaton, A.H.3    Gleason, P.P.4
  • 60
    • 83455210425 scopus 로고    scopus 로고
    • Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population
    • C.C. Wang, W.L. Chen, T.W. Kao, Y.W. Chang, C.H. Loh, and C.C. Chou Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population Clin. Ther. 33 2011 1904 1913
    • (2011) Clin. Ther. , vol.33 , pp. 1904-1913
    • Wang, C.C.1    Chen, W.L.2    Kao, T.W.3    Chang, Y.W.4    Loh, C.H.5    Chou, C.C.6
  • 62
    • 74549202936 scopus 로고    scopus 로고
    • The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database
    • N. Ziyadeh, A.T. McAfee, C. Koro, J. Landon, and K. Arnold, Chan The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database Clin. Ther. 31 2009 2665 2677
    • (2009) Clin. Ther. , vol.31 , pp. 2665-2677
    • Ziyadeh, N.1    Mcafee, A.T.2    Koro, C.3    Landon, J.4    Arnold Chan, K.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.